Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Blood-based biomarkers for Alzheimer's disease

Leuzy, Antoine LU ; Mattsson-Carlgren, Niklas LU orcid ; Palmqvist, Sebastian LU orcid ; Janelidze, Shorena LU ; Dage, Jeffrey L. and Hansson, Oskar LU orcid (2022) In EMBO Molecular Medicine 14(1).
Abstract

Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of underlying pathophysiology are playing an ever-increasing role in research, clinical trials, and in the clinical work-up of patients. Though cerebrospinal fluid (CSF) and positron emission tomography (PET)-based measures are available, their use is not widespread due to limitations, including high costs and perceived invasiveness. As a result of rapid advances in the development of ultra-sensitive assays, the levels of pathological brain- and AD-related proteins can now be measured in blood, with recent work showing promising results. Plasma P-tau appears to be... (More)

Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of underlying pathophysiology are playing an ever-increasing role in research, clinical trials, and in the clinical work-up of patients. Though cerebrospinal fluid (CSF) and positron emission tomography (PET)-based measures are available, their use is not widespread due to limitations, including high costs and perceived invasiveness. As a result of rapid advances in the development of ultra-sensitive assays, the levels of pathological brain- and AD-related proteins can now be measured in blood, with recent work showing promising results. Plasma P-tau appears to be the best candidate marker during symptomatic AD (i.e., prodromal AD and AD dementia) and preclinical AD when combined with Aβ42/Aβ40. Though not AD-specific, blood NfL appears promising for the detection of neurodegeneration and could potentially be used to detect the effects of disease-modifying therapies. This review provides an overview of the progress achieved thus far using AD blood-based biomarkers, highlighting key areas of application and unmet challenges.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
EMBO Molecular Medicine
volume
14
issue
1
article number
e14408
publisher
Wiley-Blackwell
external identifiers
  • pmid:34859598
  • scopus:85120437804
ISSN
1757-4676
DOI
10.15252/emmm.202114408
language
English
LU publication?
yes
id
0b31b926-dd0f-443a-981d-b69fd618bb6d
date added to LUP
2022-01-17 14:05:04
date last changed
2025-12-31 02:09:45
@article{0b31b926-dd0f-443a-981d-b69fd618bb6d,
  abstract     = {{<p>Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of underlying pathophysiology are playing an ever-increasing role in research, clinical trials, and in the clinical work-up of patients. Though cerebrospinal fluid (CSF) and positron emission tomography (PET)-based measures are available, their use is not widespread due to limitations, including high costs and perceived invasiveness. As a result of rapid advances in the development of ultra-sensitive assays, the levels of pathological brain- and AD-related proteins can now be measured in blood, with recent work showing promising results. Plasma P-tau appears to be the best candidate marker during symptomatic AD (i.e., prodromal AD and AD dementia) and preclinical AD when combined with Aβ42/Aβ40. Though not AD-specific, blood NfL appears promising for the detection of neurodegeneration and could potentially be used to detect the effects of disease-modifying therapies. This review provides an overview of the progress achieved thus far using AD blood-based biomarkers, highlighting key areas of application and unmet challenges.</p>}},
  author       = {{Leuzy, Antoine and Mattsson-Carlgren, Niklas and Palmqvist, Sebastian and Janelidze, Shorena and Dage, Jeffrey L. and Hansson, Oskar}},
  issn         = {{1757-4676}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{EMBO Molecular Medicine}},
  title        = {{Blood-based biomarkers for Alzheimer's disease}},
  url          = {{http://dx.doi.org/10.15252/emmm.202114408}},
  doi          = {{10.15252/emmm.202114408}},
  volume       = {{14}},
  year         = {{2022}},
}